Transaction details
William H. Carson, a director of Annexon, Inc. (NASDAQ:ANNX), acquired 8,000 shares of the company's common stock on April 10, 2026, at $6.20 per share. The total value of the purchase was $49,600. The trade was carried out pursuant to a pre-arranged Rule 10b5-1 trading plan that Carson adopted on December 8, 2025. Following the transaction, Carson's direct ownership in Annexon stands at 70,405 shares.
Share performance and current price
Over the past year Annexon’s stock has produced a substantial return of 280%. Despite that past performance, the shares are trading at $5.80, which is below the price Carson paid on April 10. The gap between the recent purchase price and the prevailing market price highlights current volatility in the stock.
Analyst coverage and company progress
Annexon has remained in the spotlight among equity analysts and company watchers. Jefferies reiterated a Buy rating with a $10.00 price target, citing merger and acquisition dynamics within the complement inhibitor space, including the referenced acquisition activity involving Biogen and Apellis Pharmaceuticals. H.C. Wainwright also reiterated a Buy recommendation and set a $14.00 price target, pointing to the distinct nature of Annexon's vonaprument as it advances through a Phase 3 trial for geographic atrophy therapy. Cantor Fitzgerald maintained an Overweight rating and drew attention to Annexon's recent submission of a Marketing Authorization Application in the European Union for tanruprubart in Guillain-Barré syndrome - the company’s first regulatory filing.
In addition to those published analyst calls, InvestingPro analysis noted that Annexon appears undervalued at current market levels and cited eight additional subscriber-only ProTips assessing the company’s financial and growth outlook.
Context and implications
The director purchase, the mix of analyst ratings, and the company's initial regulatory filing present a cluster of developments that market participants can weigh when assessing Annexon's near-term outlook. The use of a pre-arranged 10b5-1 plan is also a material detail in interpreting the timing and intent of the transaction.
Note: This article presents transaction details, analyst commentary, and regulatory milestones as reported.